Agile Therapeutics Inc (NASDAQ:AGRX) – Research analysts at William Blair issued their Q1 2020 earnings per share (EPS) estimates for shares of Agile Therapeutics in a note issued to investors on Wednesday, March 13th. William Blair analyst T. Lugo forecasts that the specialty pharmaceutical company will post earnings per share of ($0.12) for the quarter. William Blair also issued estimates for Agile Therapeutics’ Q2 2020 earnings at ($0.03) EPS, Q3 2020 earnings at $0.06 EPS and Q4 2020 earnings at $0.22 EPS.
Agile Therapeutics (NASDAQ:AGRX) last issued its earnings results on Tuesday, March 12th. The specialty pharmaceutical company reported ($0.11) EPS for the quarter, topping the consensus estimate of ($0.15) by $0.04.
Shares of AGRX opened at $1.61 on Thursday. The company has a market capitalization of $57.41 million, a PE ratio of -2.78 and a beta of 0.36. Agile Therapeutics has a 52 week low of $0.23 and a 52 week high of $3.24.
Hedge funds have recently modified their holdings of the company. BlackRock Inc. grew its holdings in shares of Agile Therapeutics by 15.7% during the fourth quarter. BlackRock Inc. now owns 133,219 shares of the specialty pharmaceutical company’s stock valued at $77,000 after buying an additional 18,038 shares in the last quarter. Geode Capital Management LLC boosted its position in Agile Therapeutics by 24.0% during the fourth quarter. Geode Capital Management LLC now owns 230,496 shares of the specialty pharmaceutical company’s stock valued at $132,000 after purchasing an additional 44,639 shares during the last quarter. Fosun International Ltd acquired a new stake in Agile Therapeutics during the third quarter valued at $180,000. Acadian Asset Management LLC lifted its position in shares of Agile Therapeutics by 260.7% in the fourth quarter. Acadian Asset Management LLC now owns 313,047 shares of the specialty pharmaceutical company’s stock worth $180,000 after buying an additional 226,255 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its position in shares of Agile Therapeutics by 54.3% in the third quarter. Renaissance Technologies LLC now owns 1,223,897 shares of the specialty pharmaceutical company’s stock worth $449,000 after buying an additional 430,907 shares during the last quarter. Institutional investors and hedge funds own 42.15% of the company’s stock.
About Agile Therapeutics
Agile Therapeutics, Inc, a women's healthcare company, focuses on the development and commercialization of prescription contraceptive products for women. Its lead product candidate is Twirla, also known as AG200-15, a once-weekly prescription combination hormonal contraceptive patch, which completed Phase III clinical trials.
Featured Story: Buy-Side Analysts
Receive News & Ratings for Agile Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Agile Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.